Quarterly report pursuant to Section 13 or 15(d)

Business combinations - Gain on bargain purchase (Details)

v3.23.3
Business combinations - Gain on bargain purchase (Details)
9 Months Ended
Jun. 01, 2023
USD ($)
Sep. 30, 2023
USD ($)
May 31, 2023
$ / shares
Mar. 06, 2023
$ / shares
Merger with TCR2 Therapeutics Inc.        
Gain on bargain purchase   $ 22,049,000    
TCR2 Therapeutics        
Merger with TCR2 Therapeutics Inc.        
Purchase consideration $ (61,726,000)      
Net assets acquired and liabilities assumed 83,775,000      
Gain on bargain purchase $ 22,049,000 22,000,000.0    
Ratio for issuance of Company's ADSs for each TCR2 stock acquired       1.5117
Closing price of Company's ADS | $ / shares     $ 1.02 $ 1.32
Amount of TCR2's earnings included in the Company's Consolidated Statement of Operations   $ 23,531,000